Pure Global AI
NCT06259058Not yet recruiting

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

Evaluate the Efficacy and Safety of Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer: a Phase Ib/II, Multicenter, Open-label Trial
Tianjin Medical University Cancer Institute and HospitalPhase 1/2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Pancreatic Cancer
Drug/Device/Intervention
Irinotecan liposome injection
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Tianjin Medical University Cancer Institute and Hospital
Timeline & enrollment
Phase
Phase 1/2
Start date
Apr 01, 2024
End date
Dec 01, 2027
Enrollment
96 participants
Primary outcome

R0 resection rate

Summary

This multicentric open-label trial will compare the efficacy and safety of stereotactic body
 radiation therapy (SBRT) followed by NALIRIFOX (5-fluorouracil, leucovorin, irinotecan
 liposome injection and oxaliplatin) vs NALIRIFOX for borderline resectable pancreatic cancer
 (BRPC).

ICD-10 classifications
Malignant neoplasm of pancreasMalignant neoplasm: Pancreas, unspecifiedMalignant neoplasm: Head of pancreasMalignant neoplasm: Tail of pancreasMalignant neoplasm: Other parts of pancreas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06259058
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06259058 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Tianjin Medical University Cancer Institute and Hospital and is currently Not yet recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 96 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.